
The proposed combination will create a differentiated global biosimilars platform that leverages Kashiv BioSciences&#39; development and manufacturing capabilities with Amneal Pharmaceuticals&#39; commercial

The proposed combination will create a differentiated global biosimilars platform that leverages Kashiv BioSciences' development and manufacturing capabilities with Amneal Pharmaceuticals' commercial strengths


Complementary acquisition will accelerate biosimilar pipeline and strengthen U.S. commercial position for affordable medicines


Kashiv BioSciences, LLC ("Kashiv"), today announced that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/AMRX">AMRX</a>) ("Amneal"). The transaction is subject to approval by Amneal shareholders, receipt of regulatory approvals and satisfaction of customary closing conditions and is expected to close in the second half of 2026.

This press release features multimedia. View the full release here: <a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260421283753/en/" rel="nofollow">https://www.businesswire.com/news/home/20260421283753/en/</a>
This acquisition combines Kashiv's extensive expertise in the development and manufacturing of biosimilars with Amneal's scale and commercialization capabilities. Kashiv is headquartered in Piscataway, New Jersey with operations in the U.S. and India. Amneal is headquartered in Bridgewater, New Jersey, and is a leading biopharmaceutical company with one of the largest affordable medicine businesses in the U.S.


Together, the companies will establish a fully integrated biosimilar platform at scale, to deliver high-quality, affordable therapies, expand patient access, and strengthen their position in the global biopharmaceutical landscape.


"We are thrilled to combine Kashiv's highly complementary portfolio and capabilities with Amneal at this critical inflection point for the biosimilar market, particularly in the U.S.," said Dr. Sandeep Athalye, Chief Executive Officer at Kashiv. "Our companies share a deep-rooted commitment to high-quality, complex medicines, and this transaction builds on the meaningful work we have accomplished through our partnership of more than ten years. We look forward to building on our proven track record of product approvals and advancing our biosimilars pipeline as we work together to expand patient access to life-changing therapies."


"As biosimilar adoption accelerates and the industry enters an unprecedented period of biologic loss of exclusivity, we see a compelling opportunity to establish leadership and scale in a rapidly expanding market," said Chirag Patel, Co-Founder and Co-Chief Executive Officer of Amneal. "With Kashiv, Amneal becomes a fully integrated global biosimilars leader at the forefront of the next wave of U.S. affordable medicines. This acquisition is a natural next step in our strategy to build a leading, diversified biopharmaceutical company, and we are confident it will drive accelerated growth and long-term value creation."


"This acquisition establishes Amneal as a fully integrated global biosimilar platform at scale," said Chintu Patel, Co-Founder and Co-Chief Executive Officer of Amneal. "By combining Kashiv's deep R&amp;D and manufacturing capabilities with our commercial strength, we are creating a differentiated platform well-positioned to deliver a strong and consistent cadence of biosimilar launches going forward. Together, we will expand access to high-quality, affordable biologic medicines for patients while driving long-term growth."


J.P. Morgan is serving as Kashiv's financial advisor for the transaction, Holland &amp; Knight LLP is serving as legal counsel, and Dhinal Shah Associates is serving as India legal counsel.


About Kashiv BioSciences
 Kashiv BioSciences, LLC is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets and is among the few U.S.-based companies to both manufacture and receive marketing authorization for multiple biosimilars. Kashiv BioSciences, LLC in the U.S., together with its subsidiaries in India (collectively, "Kashiv BioSciences") operates with robust infrastructure and highly skilled teams that provide global R&amp;D, clinical, manufacturing, regulatory, and IP capabilities. We believe our people, partners, and shared purpose fuel our work to advance patient care and access to important medicines. For additional information, please visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.kashivbiosciences.com%2F&amp;esheet=54519949&amp;newsitemid=20260421283753&amp;lan=en-US&amp;anchor=kashivbiosciences.com&amp;index=1&amp;md5=1a5655b4914a4549286847541c9baab3" shape="rect">kashivbiosciences.com</a> and follow us on <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fkashivbiosciences%2F&amp;esheet=54519949&amp;newsitemid=20260421283753&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=2&amp;md5=9b4191e577e7a1696a23f966ffba85dc" shape="rect">LinkedIn</a>.


About Amneal
 Amneal Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/AMRX">AMRX</a>), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel and built on the belief that innovation only matters if it's accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson's disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For additional information, please visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Famneal.com%2F&amp;esheet=54519949&amp;newsitemid=20260421283753&amp;lan=en-US&amp;anchor=amneal.com&amp;index=3&amp;md5=e6b755791867f6f1b86a6669aa3a0298" shape="rect">amneal.com</a> and follow us on <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Famneal-pharmaceuticals%2F&amp;esheet=54519949&amp;newsitemid=20260421283753&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=fde45b158ed95483e71bd0260b243c13" shape="rect">LinkedIn</a>.

<img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260421283753r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260421283753/en/" rel="nofollow">https://www.businesswire.com/news/home/20260421283753/en/</a>
For Kashiv BioSciences: 
 Ross Oehler
 Chief Legal Officer
 <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:ross.oehler@kashivbio.com" shape="rect">ross.oehler@kashivbio.com 
</a> 
 For Amneal Pharmaceuticals: 
 Anthony DiMeo
 VP, Investor Relations
 <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:anthony.dimeo@amneal.com" shape="rect">anthony.dimeo@amneal.com 
</a> 
 Brandon Skop
 Sr. Director, Corporate Communications
 <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:brandon.skop@amneal.com" shape="rect">brandon.skop@amneal.com</a>

AMRX

Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader

Amneal's Acquisition of Kashiv Positions It for Biosimilars Growth

Amneal Pharmaceuticals has agreed to acquire biopharma firm Kashiv BioSciences in a cash-and-stock d...

Amneal Pharma to buy Kashiv BioSciences in $1.1 billion deal

<section class="insight" data-version="1">
 <section data-block="information">
 <h3>Information</h3>
 The proposed combination will create a differentiated global biosimilars platform that leverages Kashiv BioSciences&amp;#39; development and manufacturing capabilities with Amneal Pharmaceuticals&amp;#39; commercial
 </section>

 <section data-block="ai-summary-paragraph">
 <h3>AI Summary</h3>
 Amneal Pharmaceuticals has agreed to acquire Kashiv BioSciences, aiming to create a leading biosimilars platform. This strategic move is set to strengthen Amneal&#039;s position in the market for affordable medicines and accelerate its biosimilar pipeline, potentially enhancing future revenue streams.
 </section>

 <section data-block="ai-summary-bullets">
 <h3>Key Points</h3>
 <ul><li>Amneal Pharmaceuticals to acquire Kashiv BioSciences to enhance biosimilars platform.</li><li>The deal aims to accelerate biosimilars pipeline and strengthen market position.</li><li>Transaction is expected to close in second half of 2026, pending approvals.</li><li>Combined capabilities will expand access to affordable biologic therapies.</li><li>This acquisition is viewed as a significant growth opportunity in the industry.</li></ul>
 </section>

 <section data-block="companies-mentioned">
 <h3>Companies Mentioned</h3>
 <ul><li>Amneal Pharmaceuticals (AMRX): Acquiring Kashiv to enhance growth and market position.</li><li>Kashiv BioSciences: Acquisition strengthens Amneal&#039;s capabilities in biosimilars.</li></ul>
 </section>

 <section data-block="category">
 <h3>Corporate Developments</h3>
 This news fits under &#039;Corporate Developments&#039; as it involves a strategic acquisition intended to improve Amneal&#039;s market position and product offerings in the growing biosimilars sector.
 </section>

 <section data-block="market-moving">
 <h3>Market-Moving</h3>
 <ul><li>The acquisition may lead to higher revenue projections for Amneal post-2026.</li><li>Potential synergies could reduce costs and improve margins for AMRX.</li><li>Market response to the acquisition announcement may drive AMRX shares upward.</li><li>Regulatory approvals will be crucial and may introduce volatility in stock price.</li></ul>
 </section>

 <section data-block="key-facts">
 <h3>Key Facts</h3>
 <ul><li>Acquisition from Kashiv to close in the second half of 2026.</li><li>Kashiv has a diverse portfolio in biosimilars development.</li><li>Amneal serves over 160 million prescriptions annually in the U.S.</li><li>The deal aims to expand access to affordable medicines.</li></ul>
 </section>

 <section data-block="trading-thesis">
 <h3>Trading Thesis</h3>
 Bullish on AMRX as the acquisition could significantly enhance growth over the long term.
 </section>
</section>



The proposed combination will create a differentiated global biosimilars platform that leverages Kashiv BioSciences' development and manufacturing capabilities with Amneal Pharmaceuticals' commercial strengths


Complementary acquisition will accelerate biosimilar pipeline and strengthen U.S. commercial position for affordable medicines


Kashiv BioSciences, LLC ("Kashiv"), today announced that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/AMRX">AMRX</a>) ("Amneal"). The transaction is subject to approval by Amneal shareholders, receipt of regulatory approvals and satisfaction of customary closing conditions and is expected to close in the second half of 2026.

This press release features multimedia. View the full release here: <a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260421283753/en/" rel="nofollow">https://www.businesswire.com/news/home/20260421283753/en/</a>
This acquisition combines Kashiv's extensive expertise in the development and manufacturing of biosimilars with Amneal's scale and commercialization capabilities. Kashiv is headquartered in Piscataway, New Jersey with operations in the U.S. and India. Amneal is headquartered in Bridgewater, New Jersey, and is a leading biopharmaceutical company with one of the largest affordable medicine businesses in the U.S.


Together, the companies will establish a fully integrated biosimilar platform at scale, to deliver high-quality, affordable therapies, expand patient access, and strengthen their position in the global biopharmaceutical landscape.


"We are thrilled to combine Kashiv's highly complementary portfolio and capabilities with Amneal at this critical inflection point for the biosimilar market, particularly in the U.S.," said Dr. Sandeep Athalye, Chief Executive Officer at Kashiv. "Our companies share a deep-rooted commitment to high-quality, complex medicines, and this transaction builds on the meaningful work we have accomplished through our partnership of more than ten years. We look forward to building on our proven track record of product approvals and advancing our biosimilars pipeline as we work together to expand patient access to life-changing therapies."


"As biosimilar adoption accelerates and the industry enters an unprecedented period of biologic loss of exclusivity, we see a compelling opportunity to establish leadership and scale in a rapidly expanding market," said Chirag Patel, Co-Founder and Co-Chief Executive Officer of Amneal. "With Kashiv, Amneal becomes a fully integrated global biosimilars leader at the forefront of the next wave of U.S. affordable medicines. This acquisition is a natural next step in our strategy to build a leading, diversified biopharmaceutical company, and we are confident it will drive accelerated growth and long-term value creation."


"This acquisition establishes Amneal as a fully integrated global biosimilar platform at scale," said Chintu Patel, Co-Founder and Co-Chief Executive Officer of Amneal. "By combining Kashiv's deep R&amp;D and manufacturing capabilities with our commercial strength, we are creating a differentiated platform well-positioned to deliver a strong and consistent cadence of biosimilar launches going forward. Together, we will expand access to high-quality, affordable biologic medicines for patients while driving long-term growth."


J.P. Morgan is serving as Kashiv's financial advisor for the transaction, Holland &amp; Knight LLP is serving as legal counsel, and Dhinal Shah Associates is serving as India legal counsel.


About Kashiv BioSciences
 Kashiv BioSciences, LLC is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets and is among the few U.S.-based companies to both manufacture and receive marketing authorization for multiple biosimilars. Kashiv BioSciences, LLC in the U.S., together with its subsidiaries in India (collectively, "Kashiv BioSciences") operates with robust infrastructure and highly skilled teams that provide global R&amp;D, clinical, manufacturing, regulatory, and IP capabilities. We believe our people, partners, and shared purpose fuel our work to advance patient care and access to important medicines. For additional information, please visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.kashivbiosciences.com%2F&amp;esheet=54519949&amp;newsitemid=20260421283753&amp;lan=en-US&amp;anchor=kashivbiosciences.com&amp;index=1&amp;md5=1a5655b4914a4549286847541c9baab3" shape="rect">kashivbiosciences.com</a> and follow us on <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fkashivbiosciences%2F&amp;esheet=54519949&amp;newsitemid=20260421283753&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=2&amp;md5=9b4191e577e7a1696a23f966ffba85dc" shape="rect">LinkedIn</a>.


About Amneal
 Amneal Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/AMRX">AMRX</a>), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel and built on the belief that innovation only matters if it's accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson's disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For additional information, please visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Famneal.com%2F&amp;esheet=54519949&amp;newsitemid=20260421283753&amp;lan=en-US&amp;anchor=amneal.com&amp;index=3&amp;md5=e6b755791867f6f1b86a6669aa3a0298" shape="rect">amneal.com</a> and follow us on <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Famneal-pharmaceuticals%2F&amp;esheet=54519949&amp;newsitemid=20260421283753&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=fde45b158ed95483e71bd0260b243c13" shape="rect">LinkedIn</a>.

<img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260421283753r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260421283753/en/" rel="nofollow">https://www.businesswire.com/news/home/20260421283753/en/</a>
For Kashiv BioSciences: 
 Ross Oehler
 Chief Legal Officer
 <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:ross.oehler@kashivbio.com" shape="rect">ross.oehler@kashivbio.com 
</a> 
 For Amneal Pharmaceuticals: 
 Anthony DiMeo
 VP, Investor Relations
 <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:anthony.dimeo@amneal.com" shape="rect">anthony.dimeo@amneal.com 
</a> 
 Brandon Skop
 Sr. Director, Corporate Communications
 <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:brandon.skop@amneal.com" shape="rect">brandon.skop@amneal.com</a>

Amneal Pharmaceuticals has agreed to acquire Kashiv BioSciences, aiming to create a leading biosimilars platform. This strategic move is set to strengthen Amneal's position in the market for affordable medicines and accelerate its biosimilar pipeline, potentially enhancing future revenue streams.

Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News